CANCER GENETICS,INC. (NASDAQ:CGIX) Files An 8-K Other EventsItem 8.01.Other Events
On December28, 2017, Cancer Genetics,Inc. issued a press release announcing its receipt of approximately $1,100,000 with respect to the New Jersey Technology Business Tax Certificate Transfer (NOL) Program.
Item 9.01.Financial Statements and Exhibits.
|
(d) |
ExhibitNo. |
Description |
|
99.1 |
Press Release, dated December28, 2017 |
CANCER GENETICS, INC ExhibitEX-99.1 2 a17-29002_1ex99d1.htm EX-99.1 Exhibit 99.1 Cancer Genetics Receives Non-Dilutive Funding of $1.1 Million through New Jersey Technology Business Tax Certificate Transfer (NOL) Program RUTHERFORD,…To view the full exhibit click here
About CANCER GENETICS,INC. (NASDAQ:CGIX)
Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. Its molecular- and biomarker-based diagnostic services are provided for three sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community.
